Whalesbook
Cipla Reports Margin Pressures Amid U.S. Market Challenges
Cipla's fourth-quarter fiscal year 2026 results revealed significant margin pressure and an earnings miss, driven mainly by lower U.S. revenues and ongoing supply chain issues. The company's EBITDA was INR 9.5 billion, missing analyst estimates by 7% and yielding a 15% operating margin. This compares to Q4 FY26 net profit, which dropped 54.6% year-on-year to INR 554.64 crore, while revenue fell 2.8% to INR 6,541.20 crore. For the full fiscal year, net profit declined 26.7% to INR 3,862 crore, and earnings per share fell from INR 65.29 to INR 48.03.
U.S. Revenue Slump Hits Performance
The main factor behind the earnings miss was a sharp fall in U.S. revenues. Cipla's North America business saw revenue drop 26% in INR terms year-on-year to $155 million for Q4 FY26, with full-year U.S. sales at $780 million. This decline stems from a temporary halt in Lanreotide manufacturing due to U.S. FDA observations at its contract manufacturer's facility in Greece. The expiry of exclusivity for generic Revlimid also impacted sales. Cipla is looking for an alternative U.S. manufacturing site. The company forecasts FY27 EBITDA margins between 18.5% and 20%, not including Lanreotide recovery.
Competitive Landscape and Valuation
Cipla's valuation, trading at about 22 times its projected FY28 earnings, appears less attractive compared to peers such as Natco Pharma (12.8x P/E), Zydus Lifesciences (18.4x), and Dr. Reddy's Laboratories (19.0x). Although Cipla's TTM P/E is around 20.4x-23.7x, and the broader Indian pharmaceutical sector trades at 34.55x, its growth outlook faces challenges. While the Indian pharmaceutical market grew 10.5% in Q4 FY26, the U.S. market continues to challenge many Indian firms with price erosion and intense competition, affecting companies like Cipla, Dr. Reddy's, and Zydus. Past supply chain disruptions have historically impacted Cipla's stock performance.
Key Risks and Challenges Ahead
Achieving Cipla's FY27 EBITDA margin targets of 18.5-20% and a $1 billion U.S. sales run-rate by FY27 faces significant challenges. The company heavily relies on upcoming product launches, like the generic Ventolin inhaler, for future growth. However, previous regulatory observations, including a recent USFDA Form 483 at Pharmathen's facility, show its supply chain's vulnerability and potential for launch delays. An OAI observation at Cipla's Indore facility has already delayed the Advair generic launch. The U.S. generics market also faces ongoing price erosion and buyer consolidation, increasing competitive pressure. The loss of high-margin products like gRevlimid and the Lanreotide disruption create a significant earnings challenge, especially since Lanreotide was one of Cipla's top three U.S. products. While Cipla maintains a strong net cash position of approximately INR 10,526 crore, this cannot fully overcome the operational and regulatory hurdles. An increase in intangible assets, which nearly doubled in one year and was partly debt-funded, also raises concerns.
Analyst Views and Outlook
Analyst sentiment on Cipla is mixed. Prabhudas Lilladher rates the stock 'Accumulate' with a INR 1,400 target price, based on 23x FY28E EPS. Other firms are more cautious, with TipRanks showing a 'Moderate Sell' consensus and Investing.com a 'Neutral' rating. ValueInvesting.io, however, shows a 'BUY' consensus. Most 12-month price targets are around INR 1,400-INR 1,432. A significant stock price increase depends on successfully launching key respiratory and complex generic products in the U.S. during FY27 and resolving Lanreotide supply issues, expected by late FY27 or FY28.